Steven Cohen Myriad Genetics Inc Transaction History

Point72 Asset Management, L.P.

$42.2 Billion
Q4 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Myriad Genetics Inc stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 348,604 shares of MYGN stock, worth $4.94 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

348,604

Previous 1,063,711 67.23%

Holding current value

$4.94 Million

Previous $29.1 Million 83.58%

% of portfolio

0.01%

Previous 0.08%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$13.17 - $27.03 $9.42 Million - $19.3 Million	-715,107 Reduced 67.23%	348,604 $4.78 Million
Q3 2024 Nov 14, 2024	BUY	$23.97 - $28.6 $5.38 Million - $6.41 Million	224,255 Added 26.71%	1,063,711 $29.1 Million
Q2 2024 Aug 14, 2024	BUY	$17.98 - $25.47 $1.1 Million - $1.56 Million	61,260 Added 7.87%	839,456 $20.5 Million
Q1 2024 May 15, 2024	BUY	$17.59 - $23.59 $13.7 Million - $18.4 Million	778,196 New	778,196 $16.6 Million
Q3 2023 Nov 14, 2023	BUY	$15.99 - $23.22 $41,589 - $60,395	2,601 Added 7431.43%	2,636 $42,000
Q2 2023 Aug 14, 2023	BUY	$17.56 - $23.76 $614 - $831	35 New	35 $0
Q1 2023 May 15, 2023	SELL	$15.26 - $23.75 $408,968 - $636,500	-26,800 Closed	0 $0
Q4 2022 Feb 14, 2023	SELL	$14.51 - $20.99 $5.48 Million - $7.93 Million	-377,608 Reduced 93.37%	26,800 $388,000
Q3 2022 Nov 14, 2022	BUY	$18.21 - $27.88 $3.19 Million - $4.88 Million	175,163 Added 76.41%	404,408 $7.72 Million
Q2 2022 Aug 15, 2022	BUY	$16.45 - $25.88 $1.34 Million - $2.11 Million	81,648 Added 55.32%	229,245 $4.17 Million
Q1 2022 May 16, 2022	BUY	$22.67 - $28.01 $3.35 Million - $4.13 Million	147,597 New	147,597 $3.72 Million
Q4 2021 Feb 14, 2022	SELL	$24.13 - $32.63 $5.78 Million - $7.81 Million	-239,493 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$29.97 - $36.66 $4.27 Million - $5.22 Million	-142,312 Reduced 37.27%	239,493 $7.73 Million
Q2 2021 Aug 16, 2021	SELL	$25.39 - $32.61 $407,331 - $523,162	-16,043 Reduced 4.03%	381,805 $11.7 Million
Q1 2021 May 17, 2021	BUY	$19.92 - $31.6 $572,500 - $908,184	28,740 Added 7.79%	397,848 $12.1 Million
Q4 2020 Feb 16, 2021	BUY	$12.16 - $19.77 $4.2 Million - $6.82 Million	345,029 Added 1432.9%	369,108 $7.3 Million
Q3 2020 Nov 16, 2020	BUY	$11.25 - $14.75 $270,888 - $355,165	24,079 New	24,079 $314,000
Q2 2020 Aug 14, 2020	SELL	$10.69 - $16.49 $1.51 Million - $2.33 Million	-141,500 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$9.78 - $29.53 $1.22 Million - $3.69 Million	124,839 Added 749.29%	141,500 $2.03 Million
Q4 2019 Feb 14, 2020	SELL	$20.93 - $35.1 $2.54 Million - $4.26 Million	-121,253 Reduced 87.92%	16,661 $454,000
Q3 2019 Nov 15, 2019	SELL	$22.08 - $47.08 $18.7 Million - $39.8 Million	-844,687 Reduced 85.96%	137,914 $3.95 Million
Q2 2019 Aug 14, 2019	BUY	$22.67 - $35.0 $8.15 Million - $12.6 Million	359,488 Added 57.69%	982,601 $27.3 Million
Q1 2019 May 15, 2019	SELL	$26.93 - $34.7 $8.44 Million - $10.9 Million	-313,394 Reduced 33.46%	623,113 $20.7 Million
Q4 2018 Feb 14, 2019	BUY	$27.23 - $45.56 $8.88 Million - $14.9 Million	326,187 Added 53.45%	936,507 $27.2 Million
Q3 2018 Nov 14, 2018	SELL	$37.57 - $50.34 $8.49 Million - $11.4 Million	-225,880 Reduced 27.01%	610,320 $28.1 Million
Q2 2018 Aug 14, 2018	SELL	$27.75 - $40.17 $1.3 Million - $1.87 Million	-46,674 Reduced 5.29%	836,200 $31.2 Million
Q1 2018 May 15, 2018	BUY	$28.83 - $41.01 $545,636 - $776,155	18,926 Added 2.19%	882,874 $26.1 Million
Q4 2017 Feb 14, 2018	BUY	$28.45 - $37.14 $24.6 Million - $32.1 Million	863,948	863,948 $29.7 Million

Others Institutions Holding MYGN

# of Institutions

227

Shares Held

92M

Call Options Held

297K

Put Options Held

20.7K

View Full List

About MYRIAD GENETICS INC

Ticker MYGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 80,634,800
Market Cap $1.14B
Description
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...

More about MYGN

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account